At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 73 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Lung Cancer. Completed, enrolled 73 participants across 19 sites.
Detailed Summary
Exploratory phase II trial of intravenous (IV) Pembrolizumab MK-3475 as second or further line with advanced Non-small cell Lung Cancer (NSCLC) who have failed to a prior treatment with anti-PDL1 drug. Pembrolizumab 200 mg ,Q3W, IV infusion, Day 1 of each 3 week cycle will be administered until disease progression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJul 2018
Primary CompletionDec 2022
Study CompletionMar 2023
TodayJul 2026
First PostedMay 16, 2018
Enrollment StartJul 15, 2018
Primary CompletionDec 30, 2022
Study CompletionMar 9, 2023
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.1 years ago
Interventions
Pembrolizumabdrug
200 mg, Q3W
Pembrolizumabdrug
200 mg, Q3W